Becker Muscular Dystrophy (BMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Becker muscular dystrophy (BMD) is an X-linked recessive allelic muscular dystrophy caused by mutations in the DMD gene. BMD is characterised by less severe clinical phenotypes than DMD, with onset mostly during school age, between 5-15 years old, even though there are several reported cases of late-onset BMD in the third and fourth decades of life. BMD clinical phenotypes are varied, ranging from mild symptoms, such as muscle cramps, myalgia, myoglobinuria and mild myopathy, to severe myopathy that can interfere with patient’s ability to walk. Cardiac involvement has been reported in 70% of BMD cases. The most common type of cardiac abnormality is dilated cardiomyopathy, which is associated with congestive heart failure and premature death.
• The incidence of Becker muscular dystrophy (BMD) has been estimated to be between 1 in 18,000 and 1 in 30,000 male births.
• The prevalence of BMD is estimated to be 17 to 27 cases per million people. Female carriers of X-linked recessive conditions have a 50% (1 in 2) risk of passing the mutated gene to each child. Male children have a 50% risk of being affected, and female children have a 50% risk of being a carrier.

Thelansis’s “Becker Muscular Dystrophy (BMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Becker Muscular Dystrophy (BMD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Becker Muscular Dystrophy (BMD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Becker Muscular Dystrophy (BMD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Becker Muscular Dystrophy (BMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Becker Muscular Dystrophy (BMD), Becker Muscular Dystrophy (BMD) market outlook, Becker Muscular Dystrophy (BMD) competitive landscape, Becker Muscular Dystrophy (BMD) market forecast, Thelansis, Primary market research, KOL insights, Com